News Takeda Pharmaceutical Company Limited Sao Paulo

Equities

TAKP34

BRTAKPBDR006

Market Closed - Sao Paulo Other stock markets 11:36:04 21/06/2024 pm IST			5-day change	1st Jan Change
68.53 ^BRL	-1.01%		-5.23%	-0.91%

21/06	Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	MT
21/06	Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	DJ

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	22/06	MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	22/06	DJ
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	22/06	BU
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	21/06	AQ
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	21/06	MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	21/06	RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	21/06	MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	21/06	CI
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	19/06	AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	18/06	AQ
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	18/06	MT
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting	18/06	BU
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	18/06	CI
Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes	18/06	MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	17/06	DJ
Sector Update: Health Care Stocks Decline Premarket Monday	17/06	MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	17/06	MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	17/06	MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	17/06	MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	17/06	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited Sao Paulo

Equities

TAKP34

BRTAKPBDR006

Summary

Filters